June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Full-Thickness Macular Hole (FTMH) and Vitreomacular Traction (VMT): Comparison of visual results in patients receiving pars plana vitrectomy (PPV) for FTMH in one eye and ocriplasmin in the contralateral eye
Author Affiliations & Notes
  • Greggory Gahn
    University of Nevada, Reno School of Medicine, Reno, Nevada, United States
  • Arshad M Khanani
    Sierra Eye Associates, Reno, Nevada, United States
  • Victor H Gonzalez
    Valley Retina Institute, McAllen, Texas, United States
  • Joseph I Markoff
    Wills Eye Hospital, Philadelphia, Pennsylvania, United States
    Thomas Jefferson Medical College, Philadelphia, Pennsylvania, United States
  • Hamzah Khalaf
    Valley Retina Institute, McAllen, Texas, United States
  • Footnotes
    Commercial Relationships   Greggory Gahn, None; Arshad Khanani, ThromboGenics (C); Victor Gonzalez, ThromboGenics (C); Joseph Markoff, ThromboGenics (C); Hamzah Khalaf, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3697. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Greggory Gahn, Arshad M Khanani, Victor H Gonzalez, Joseph I Markoff, Hamzah Khalaf; Full-Thickness Macular Hole (FTMH) and Vitreomacular Traction (VMT): Comparison of visual results in patients receiving pars plana vitrectomy (PPV) for FTMH in one eye and ocriplasmin in the contralateral eye. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3697.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine if there is a difference in Best Corrected Visual Acuity (BCVA) in patients with VMT in one eye and a FTMH in the other. The eye with the FTMH received PPV while that with traction only, without a FTMH, received ocriplasmin.

Methods : Nine patients received a single injection of 0.125mg ocriplasmin (for traction alone) or PPV (for FTMH) to initially treat this condition. After the first eye was treated, with one of the two treatment options and was stable, the second eye was treated with the opposite modality. The interval between treatments averaged 4.6 months. All patients were female with ages ranging from 60 to 78 years. Three eyes were phakic OU and 6 eyes were pseudophakic OU. There were two different study sites and two surgeons (VG, AK) who performed the PPV and administered the injections. BCVA was measured at baseline (BL), 3 months, 6 months and in some patients up to two years. The mean follow up was 14 months. The order of treatment was not randomized. The eye with the worst BCVA at BL was treated first. Seven patients had PPV first while two patients had ocriplasmin as the initial treatment.

Results : Patients in both groups had successful anatomical resolution. None of the ocriplasmin patients required subsequent PPV for VMT release. Patients who received ocriplasmin had a mean BCVA at BL of 20/61 and a final visual acuity of 20/34. In the PPV group the mean BL visual acuity was 20/156 and at study end it was 20/53. There were no statistical differences in final BCVA between these two groups. There were no differences with respect to lens status or patient age. There were no sex differences since all were female.

Conclusions : Patients with VMT in one eye and a history of FTMH in the fellow eye who underwent PPV for FTMH benefit from early ocriplasmin treatment and could avoid the development of a FTMH in the other eye and thus a second PPV.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×